Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The major causes of thrombocytopenia are inefficient production of platelets, platelet splenic sequestration, and accelerative destruction of platelets. Thrombocytopenia can be inherited or acquired and the most common ineffective production of thrombocytes are due to bone marrow failure syndromes such as myelodysplastic syndrome and aplastic anemia. In 2014, according to a research article published in 2014, titled 'Frequency of Thrombocytopenia', the frequency of thrombocytopenia is higher in people aged 60 years and above who are suffering from non-cirrhotic liver disease. However, rampant discovery coupled with the ability to clone thrombopoietin has resulted in new treatment opportunities for clinical manifestation.
The Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market size was valued at US$ 82.23 million in 2019, and is expected to witness a CAGR of 4.0% over the forecast period (2019 – 2027).
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market Share (%) Analysis, By Drug Type, 2019
Source: Coherent Market Insights Analysis (2019)
Increasing Drug Approvals & Launches are expected to Drive Growth of the Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market
Increasing launch of new drugs by key players operating in the ITP treatment drugs market is expected to boost the market growth. Key players are focused on research and development of new drugs to address unmet need of patients with ITP disease. For instance, in June 2019, Dova Pharmaceuticals, Inc. received the U.S. FDA approval for a supplemental New Drug Application (sNDA) to expand the use of the DOPTELET (avatrombopag) drug for treatment of chronic immune thrombocytopenia (ITP) in adults who had a deficient response to previous treatment. Dova Pharmaceuticals, Inc. is expected to launch DOPTELET in Asia Pacific, Middle East, and Africa in 2021.
Increasing healthcare infrastructure and spending on development of better medical facilities in the Middle East is expected to accelerate growth of the Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market over the forecast period. For instance, in November 2019, the Sheikh Shakhbout Medical City (SSMC), one of the 10 largest hospitals in the United Arab Emirates (UAE), started a 3.2-million square foot project. The new facility which is located in Abu Dhabi will offer improved access to healthcare for residents. The hospital is the first of its kind in the UAE to provide advanced treatment procedures and expand access to specialty care services such as orthopedic and thoracic surgery.
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market - Restraints
To treat ITP, alternative surgical procedures such as splenectomy and bone marrow transplant are often the choice of treatment because of better outcomes. These factors are expected to hamper growth of the Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market over the forecast period. For instance, according to data published by Al-Aqsa University Journal in January 2017, Splenectomy cures ITP by removing both the primary site of platelet destruction and an important site of antiplatelet antibody production in a large proportion of patients. According to the same source, laparoscopic splenectomy has recorded a success rate of 72% at 5 years. Sustained responses were observed in 60–80% of ITP patients undergoing splenectomy in 2017.
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market - Regional Insights
Turkey is expected to hold a dominant position in the Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market owing to strategic collaborations by key players in order to distribute their products all over the country, which, in turn, is aiding the growth of the Turkey immune thrombocytopenia purpura market. For instance, in January 2019, Rigel Pharmaceuticals, Inc. collaborated and entered into an exclusive license and supply agreement with Spain-based Grifols S.A, to commercialize fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey.
Saudi Arabia is expected to foresee a rapid growth in the Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market. Saudi Arabia is expected to gain momentum owing to increasing prevalence of immune thrombocytopenia purpura among pediatric population in the country over the forecast period. For instance, according to a study report by King Khalid University of Saudi Arabia, published in December 2014, around 86% of pediatric cases of ITP are under the age of 6. As per the same source, 58% of the pediatric patients are female.
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027
Source: Coherent Market Insights Analysis (2019)
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market - Competitive Landscape
Key players operating in the Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market include Amgen Inc., Octapharma AG, Novartis AG, Swedish Orphan Biovitrum AB, and Rigel Pharmaceuticals, Inc.
Two therapies are used for treatment of ITP in Middle East, and it is categorized into first-line therapy (Corticosteroids, intravenous immunoglobulin (IVIG), and anti-D immune globulin) and second-line therapy (thrombopoietin receptor agonists, monoclonal antibody). However, despite availability of these therapies, some patients still remain refractory to the treatment.
The ongoing research for treatment of ITP is focused on combining therapies and addressing multiple mechanisms of the disease simultaneously. As per data published by the American Society of Hematology in July 2018, the emerging combination therapies for ITP treatment are the combination of drugs, dexamethasone and rituximab which has been examined in several trials and has been indicated to provide superior results to either drug as monotherapy in some patients, and the possibility to revert lymphocyte subset abnormalities commonly seen in active disease. The addition of cyclosporine to rituximab and dexamethasone has also been evaluated in small adult studies and has provided enduring remission in a subset of treated patients, without substantial reported toxicity.
Increasing prevalence of immune thrombocytopenic purpura in pediatric population is expected to drive growth of the immune thrombocytopenic purpura drugs market in Middle East and Turkey. For instance, according to data published by the Paediatric Blood Cancer journal in 2013, around 10% of children with acute immune thrombocytopenia purpura were admitted to hospitals in Egypt in 2013.
The immune thrombocytopenic purpura drugs market growth in the Middle East and Turkey is expected to be hampered, owing to slower execution of rules and regulations regarding the approval and launch of treatment drugs compared to North America and Europe. For instance, in the Middle East, Amgen Inc.'s Nplate (romiplostim) is the only drug currently available for treatment of immune (idiopathic) thrombocytopenic purpura (ITP). This drug is present in the U.S. since 2003. Later in 2006, Amgen launched it in Israel, Kuwait, Egypt, and Lebanon.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.